Literature DB >> 8028787

Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.

H Mochizuki1, H Imai, K Endo, K Yokomizo, Y Murata, N Hattori, Y Mizuno.   

Abstract

The mechanism of abnormal iron accumulation in the substantia nigra (SN) pars compacta of patients with Parkinson's disease (PD) is unknown. To explore this question, we made a hemiparkinsonism model in monkeys by injecting 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the caudate or putamen on one side, and compared iron content in the SN and other basal ganglia structures by histochemistry. The injected side, especially the SN pars compacta, showed a marked increase in iron staining. Our study indicates that an injury to the nigrostriatal system by MPTP injection can induce iron accumulation in the SN.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8028787     DOI： 10.1016/0304-3940(94)90462-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  21 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.

Authors:  Moussa B.H. Youdim; Edna Grünblatt; Yona Levites; Gila Maor; Silvia Mandel
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

3.  Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.

Authors:  A Fredriksson; N Schröder; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

4.  Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells.

Authors:  Wen-Jing Li; Hong Jiang; Ning Song; Jun-Xia Xie
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

5.  Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.

Authors:  C C Chiueh; T Andoh; A R Lai; E Lai; G Krishna
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice.

Authors:  M B H Youdim; E Grünblatt; S Mandel
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

7.  Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity.

Authors:  Muralikrishnan Dhanasekaran; Christian B Albano; Lori Pellet; Senthilkumar S Karuppagounder; Subramaniam Uthayathas; Vishnu Suppiramaniam; Holly Brown-Borg; Manuchair Ebadi
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

8.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

9.  Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.

Authors:  Nadia G Innamorato; Agnieszka Jazwa; Ana I Rojo; Concepción García; Javier Fernández-Ruiz; Anna Grochot-Przeczek; Anna Stachurska; Alicja Jozkowicz; Jozef Dulak; Antonio Cuadrado
Journal:  PLoS One       Date:  2010-07-28       Impact factor: 3.240

Review 10.  Iron accumulation in Parkinson's disease.

Authors:  Hideki Mochizuki; Toru Yasuda
Journal:  J Neural Transm (Vienna)       Date:  2012-10-16       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.